Roles of glycoprotein glycosylation in the pathogenesis of an endemic osteoarthritis, Kashin-Beck disease, and effectiveness evaluation of sodium hyaluronate treatment

SEN WANG
ZONGQIANG GAO
HUAN LIU
PEILIN MENG
CUIYAN WU

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
WANG, SEN; GAO, ZONGQIANG; LIU, HUAN; MENG, PEILIN; WU, CUIYAN; LAMMI, MIKKO; and GUO, XIONG (2020) "Roles of glycoprotein glycosylation in the pathogenesis of an endemic osteoarthritis, Kashin-Beck disease, and effectiveness evaluation of sodium hyaluronate treatment," Turkish Journal of Medical Sciences: Vol. 50: No. 4, Article 51. https://doi.org/10.3906/sag-1903-137
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss4/51

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
Roles of glycoprotein glycosylation in the pathogenesis of an endemic osteoarthritis, Kashin-Beck disease, and effectiveness evaluation of sodium hyaluronate treatment

Authors
SEN WANG, ZONGQIANG GAO, HUAN LIU, PEILIN MENG, CUIYAN WU, MIKKO LAMMI, and XIONG GUO

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol50/iss4/51
Roles of glycoprotein glycosylation in the pathogenesis of an endemic osteoarthritis, Kashin–Beck disease, and effectiveness evaluation of sodium hyaluronate treatment

Sen WANG, Zongqiang GAO, Huan LIU, Peilin MENG, Cuiyan WU, Mikko J. LAMMI, Xiong GUO

1School of Public Health, Health Science Center, Xi'an Jiaotong University; Key Laboratory of Trace Elements and Endemic Diseases, National Health Commission, Xi'an, Shaanxi, P. R. China
2Orthopedic Department, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China
3Department of Integrative Medical Biology, University of Umeå, Umeå, Sweden

1. Introduction
Kashin–Beck disease (KBD) is an endemic osteoarthritis, which is characterized by chondrocyte necrosis and apoptosis, cartilage degeneration, and extracellular matrix degradation. It is endemic in a crescent-shaped area extending from southeastern Siberia to northeastern and southwestern China. It affects approximately 690,000 people and poses a high risk to 10.584 million others residing in 366 counties within 14 provinces or autonomous regions of China, according to the 2010 Health Statistical Yearbook of China [1].

The capacity for hyaluronate synthesis is decreased in chondrocytes from patients with KBD. Exogenous hyaluronate increases its synthesis in chondrocytes, which provides the foundation for the theory that the KBD patient should be treated with an intraarticular injection of hyaluronate. Compared with the normal control group, IL-1β and TNF-α levels were higher in the KBD group, while their expression levels decreased after administration of hyaluronate [2]. The levels of type II collagen and aggrecan mRNAs were also lower in the KBD group. After the administration of different doses of hyaluronate (100 and 500 mg/mL), their levels were significantly increased;
500 mg/mL treatment led to a more significant effect [3]. Intraarticular injections of sodium hyaluronate effectively reduced knee pain caused by KBD to a baseline value measured by using the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index [4].

Protein glycosylation plays a key role in a number of biological processes, such as development, maintenance of normal cellular functions, intercellular signaling, protein folding, protein–protein interactions, cellular differentiation, metabolism, and bacterial infections. About half of human proteins are considered to be modified with different glycosylation patterns [5]. Lectins are carbohydrate-binding proteins which have been used to discriminate carbohydrate structures, including glycosaminoglycans, glycolipids, and glycoproteins in a high-throughput manner based on slight structural differences [6]. Oligosaccharides, which exist in human saliva, include amino sugars, galactose, sialic acids (Sia), xylose, fucose, and mannose. Proteins, which perform many diverse functions, are modified by the glycan parts of glycoproteins [7]. A lectin microarray is one of the main ways to investigate variable glycosylation, as it can test many different glycan bindings simultaneously [8].

The etiology of KBD remains unclear. Its pathogenesis has not yet been fully defined. Currently, there are no diagnostic or treatment follow-up indicators available for KBD based on glycoprotein levels. In this study, we have suggested that the glycosylation change in the salivary and serous glycoproteins may involve the pathogenesis of KBD, and may play a role in guiding treatment. Therefore, we aimed at revealing whether such glycosylation pattern differences are present in the saliva and serum of KBD patients, and to investigate the role of knee joint injection of sodium hyaluronate on the glycosylation in the KBD patients. Lectin microarray was used to detect the expression patterns of glycosylations. Reversed microarrays and lectin blot were used to validate the results of lectin microarray. Finally, this study evaluated whether the identified potential lectins could be effective as diagnostic biomarkers for KBD, and useful in the follow-up of sodium hyaluronate treatment of KBD.

2. Materials and methods
2.1. Whole saliva and venous blood samples collection
Patients with KBD (n = 35; 20 males, 15 females, 61 ± 5 years old) and normal control individuals (n = 38; 20 males, 18 females, 60 ± 6 years old) were recruited from Linyou and Yongshou counties in Shaanxi Province, China. All samples were excluded if the persons showed genetic indications of bone or cartilage diseases, osteoarthritis, or rheumatoid arthritis. Sodium hyaluronate (10 mg/mL, 2 mL) was injected into a knee joint of each patient with KBD. Both venous blood and saliva were collected from the KBD patients before and 2 weeks after the injection (untreated KBD group, n = 35; treated KBD group, n = 35). Samples were also collected from the matched normal group (n = 38). At least 2 h after the last intake of food, 3 mL of peripheral blood and 3 mL of unstimulated saliva were collected; 0.9% saline was used to rinse participant's mouth before saliva was collected. Protease inhibitor cocktail (1 µL/mL of saliva; Sigma, Darmstadt, Germany) was added to the saliva immediately after collection. The saliva was then centrifuged at 12,000 rpm, 30 min, 4 °C. The supernatant was stored at −80 °C. Venous blood samples were incubated at room temperature for 30 min. The serum was collected by centrifugation at 3000 rpm for 5 min and then used immediately or stored at −80 °C.

Informed consent was obtained from each subject involved in the investigation. All procedures performed in the study involving human participants were in accordance with the ethical standards of the Declaration of Helsinki as revised in 1964. The study has the ethical approval of the Ethics Management Committee of Xi’an Jiaotong University (No: 2019-639).

2.2. Saliva and serum lectin microarrays
Twenty samples of saliva or serum from both the untreated and the treated KBD groups were applied to the lectin microarray. In addition, 20 samples from the control group were also applied to the lectin microarray. Samples from the untreated KBD, the treated KBD, and normal groups were divided into subgroups by age (±5 years) separately. The samples in each subgroup were pooled into one sample separately. Pooled samples were then matched according to sex. Saliva and serum lectin microarrays were produced separately and incorporated 37 lectins (Sigma, Darmstadt, Germany), which bind N- or O-linked glycans (shown in Table 1). The arrangement of the lectin microarray is shown in Figure 1. In brief, 37 lectins were dissolved in the manufacturer's recommended buffer and then spotted on the homemade epoxysilane-coated slides with Stealth microspotting pins (SMP-10B; TeleChem, Sunnyvale, CA, USA) with a Capital smart microarrayer (CapitalBio, Beijing, China). Every lectin was spotted in triplicate on one slide. The protein labeled with Cy3 was diluted in 0.5 mL buffer containing 2% glycine, bovine serum albumin (BSA), and 0.1% Tween-20. The mixture was then used in the lectin microarrays. Finally, incubation was performed in the chamber at 37 °C for 3 h [9].

2.3. Statistical analysis of saliva and serum lectin microarrays
Three replicate slides of each sample were consistently analyzed. We obtained primary fluorescence intensity value of each lectin, then each value was globally normalized by getting the ratio of each intensity value compared with the sum of 37 lectin values. The mean of 3 replicate ratios was the final fluorescence intensity value of each lectin.
### Table

The structures of the carbohydrate chains recognized especially by the lectins.

| Lectin | Full name of the lectin | Specificity carbohydrate chain |
|--------|--------------------------|--------------------------------|
| ACA    | *Amaranthus caudatus*    | Galβ1-3GalNAcα-Ser/Thr (T antigen), sialyl-T(ST) tissue staining patterns are markedly different than those obtained with either PNA or Jacalin |
| AAL    | *Alcavilia aurantia*     | Fuca1-6 GlcNAc(core fucose), Fuca1-3(Galβ1-4)GlcNAc |
| BPL    | *Bauchinia purpurea*     | Galβ1-3GalNAc, Terminal GalNAc |
| BS-I   | *Bandeiraea simplicifolia* | α-Gal, α-GalNAc, Galα1-3Gal, Galα1-6Glc |
| ConA   | *Canavalia ensiformis*   | High Mannose, Manα1-6(Mana1-3)Man, αMannose, αGlc |
| DBA    | *Dolichos biflorus*      | αGalNAc, Tn antigen, GalNAca1-3((Fuca1-2))Gal (blood group A antigen) |
| DSA    | *Datura stramonium*      | (GlcNAc) 2-4, polyLacNAc and LacNAc (NA3, NA4) |
| ECA    | *Erythrina cristagalli*  | Galβ1,4GlcNAc (type II), Galβ1-3GlcNAc (type I) |
| EEL    | *Euonymus europaeus*     | Galα1-3(Fuca1-2)Gal (blood group B antigen) |
| GNA    | *Galanthus nivalis*      | High-Mannose, Manα1-3Man |
| GSL-I  | *Griffonia (Bandeiraea) simplicifolia* lectin I | αGalNAc, αGal, anti-A and B |
| GSL-II | *Griffonia (Bandeiraea) simplicifolia* lectin II | GlcNAc and agalactosylated tri/tetra antenenary glycans |
| HHL    | *Hippeastrum hybrid lectin* | High-Mannose, Manα1-3Man, Manα1-6Man, Man5-GlcNAc2-Asn |
| Jacalin| *Artocarpus integrifolia* | Galβ1-3GalNAcα-Ser/Thr(T), GalNAco-Ser/Thr(Tn), GlcNAcb1-3-GalNAcα-Ser/Thr(Core3), sialyl-T(ST). not bind to Core2, Core6, and sialyl-Tn (STn) |
| LCA    | *Lens culinaris* agglutinin | α-D-Man, Fuco1-6GlcNAc, α-D-Glc |
| LEL    | *Lycopersicon esculentum* (tomato) lectin | (GlcNAc)_α, high mannosetype N-glyscons |
| LTL    | *Lotus tetragonolobus*   | Fuca1-3Galβ1-4GlcNAc, Fuca1-anti-H blood group specificity |
| MAL-I  | *Maackia amurensis* lectin I | Galβ1,4GlcNAc |
| MAL-II | *Maackia amurensis* lectin II | Sia2-3Galβ1-4GlcNAcα/Glc, Sia2a-3Gal, Sia2-3, Sia2a-3-GalNAc |
| MPL    | *Maclura pomifera* lectin | Galβ1-3GalNAc, GalNAc |
| NPA    | *Narcissus pseudonarcissus* lectin | High-Mannose, Manα1-6Man |
| PHA-E+L| *Phaseolus vulgaris* agglutinin (E+L) | Bisecting GlcNAc, bi-antenenary N-glyscons, tri- and tetra-antenenary complex-type N-glycan |
| PWM    | *Phytolaccuc americana*  | (GlcNAc)_α and polyLacNAc |
| PSA    | *Pisum sativum* agglutinin | Fuco1,6GlcNAcα-D-Man, α-D-Glc |
| PHA-E  | *Phaseolus vulgaris* agglutinin (E) | Bisecting GlcNAc, bi住tenenary complex-type N-glycan with outer Gal |
| PTL-I  | *Psophocarpus tetragonolobus* lectin I | GalNAc, GalNAcα1-3Gal, GalNAcβ1-3Galα1-3,4Glc |
| PTL-II | *Psophocarpus tetragonolobus* lectin II | Gal, blood group H, T-antigen |
| PNA    | *Peanut agglutinin*      | Galβ1-3GalNAcα-Ser/Thr(T) |
| RCA120 | *Ricinus communis* agglutinin I | β-Gal, Galβ1,4GlcNAc (type II), Galβ1-3GlcNAc (type I) |
| SJA    | *Sophora japonica* agglutinin | Terminal in GalNAc and Gal, anti-A and anti-B human blood group |
| STL    | *Solanum tuberosum* (potato) lectin | Trimmers and tetramers of GlcNAc, core (GlcNAc) of N-glycan, oligosaccharide containing GlcNAc and MurNAc |
| SBA    | *Soybean agglutinin*     | α- or β-linked terminal GalNAc, (GlcNAc)_α, GalNAcα1-3Gal, blood-group A |
| SNA    | *Sambucus nigra* lectin  | Sia2-6Gal/GalNAc |
| UEA-I  | *Ulex europaeus* agglutinin I | Fuca1-2Galβ1-4GlcNAc |
| VVA    | *Vicia villosa* lectin   | Terminal GalNAc, GalNAcα-Ser/Thr(Tn), GalNAcα1-3Gal |
| WFA    | *Wisteria floribunda* lectin | Terminating in GalNAcα/β1-3/6Gal |
| WGA    | *Triticum vulgaris*      | Multivalent Sia and (GlcNAc)_α |
Subsequently, we separately compared the means of paired groups (untreated KBD/treated KBD, untreated KBD/normal, and treated KBD/normal). Fold changes ≥1.5 or ≤0.67 between the pairs indicated up- or down-regulation of each lectin, respectively.

2.4. Saliva and serum reversed microarrays verification
A reversed microarray analysis was used to verify the lectin microarray results. Salivary and serous protein samples from 15 untreated KBD patients, 15 KBD patients treated with sodium hyaluronate, and 18 normal individuals were spotted in triplicate on the microarray. The Cy3-labeled lectins were applied to detect the specific glycan structures in the salivary and serous protein samples, which were immobilized on the slides. Lectins GSL-I, SNA, and Jacalin were selected for saliva microarrays, and HHL, AAL, and PNA for serum microarrays. The slides were scanned using a Genepix 4000B confocal scanner, and the acquired images were analyzed at 532 nm to detect Cy3.

2.5. Statistical analysis of saliva and serum microarrays verification
Significant differences between the untreated KBD, the treated KBD, and the normal groups were calculated using one-way ANOVA with SPSS Statistics 19 (IBM, Armonk, NY, USA). Differences were considered statistically significant for values of P < 0.05.

2.6. Lectin blot analysis
In order to further confirm the different abundance of significant glycans, the SDS-PAGE and lectin blotting analysis was performed with 3 lectins (HHL, AAL, and Jacalin) in pooled saliva group samples and 4 lectins (HHL, PNA, PHA-E+L, and AAL) in both pooled saliva group samples and pooled serum group samples of the normal control, the untreated KBD, and the treated KBD groups separately. In brief, the samples were run on a 10% SDS-PAGE polyacrylamide resolving gel and a 3% stacking gel. Afterwards, the proteins in the gels were transferred to a PVDF membrane (MilliporeSigma, Burlington, MA, USA) with a wet transfer unit (Hoefer Scientific, Holliston, MA, USA) at 100 V for 1.5 h. The membrane was washed twice with TTBS (10 mmol/L Tris-HCl, 150 mmol/L NaCl, 0.05% Tween-20, pH 7.5) and blocked with Carbo-Free Blocking Solution (Vector, Burlingame, CA, USA) for 1 h at room temperature. The membrane was incubated with Cy5-labeled (GE Healthcare, Buckinghamshire,
UK) lectins (2 mg/) at 4 °C overnight in the dark. Finally, the membrane was scanned using a phosphorimager (Molecular Dynamics Inc., Sunnyvale, CA, USA) [9].

3. Results

3.1. Differential lectins in saliva and serum lectin microarrays

Saliva lectin microarray showed significant differences in the fluorescence intensities of 8 lectins between the untreated KBD, the treated KBD, and the normal groups (Figure 2). Stronger signals for SJA, GSL-I, EEL, MAL-II, SNA, HHL, and AAL were observed in the saliva from the untreated KBD patients than from the treated patients with KBD and the control group. Meanwhile, Jacalin signal was lower in the saliva from the untreated KBD patients and the treated KBD group in comparison with the control group. After hyaluronate treatment, the levels of SNA, AAL, and MAL-II appeared to return to approximately normal levels.

In the serum lectin microarray (Figure 3), significant differences in the fluorescence intensities of 5 lectins were observed between the untreated KBD, the treated KBD, and the control groups. Strong signals of HHL and PNA were typical for the samples of the untreated KBD group in comparison to the normal ones. Meanwhile, decreased AAL, PHA-E+L, and PTL-I signals were observed in the serum samples of the KBD patients. Hyaluronate treatment appeared to normalize the levels of HHL, PNA, AAL, PHA-E+L, and PTL-I.

3.2. Differential lectins in saliva and serum microarrays verification

Salivary protein microarray showed significantly stronger GSL-I signal in the untreated KBD patients (Figure 4). Significantly elevated SNA signal levels in the untreated patients were normalized by the hyaluronate treatment, although the level still remained higher than in the control group (Figure 4). Saliva from the untreated patients had significantly lower levels of Jacalin than the healthy controls (Figure 4).

Data from serum microarray verification showed that significantly increased levels of HHL and PNA signals in the untreated KBD group declined to the control level in the treated group (Figure 5). A significantly decreased level of AAL signal in the untreated KBD group increased to the control level in the treated group (Figure 5).

3.3. Lectin blot analysis

The different abundance of glycans among normal control (healthy), the untreated KBD (UK), and the treated KBD (TK) groups were confirmed by the lectin blotting analysis with 3 lectins (HHL, AAL, and Jacalin) in saliva samples and 4 lectins in serum samples (HHL, PNA, PHA-E+L, and AAL). The results of the lectin blotting analysis showed...
showed apparent bands belonging to different molecular weights ranging from 15 to 250 kDa. The apparent bands were marked as L1–L10 (Figures 6 and 7).

Among the selected lectins, HHL showed stronger binding to 2 bands between 70 and 100 kDa (L1, L2), 2 bands between 25 and 50 kDa (L4, L5), and 1 band between 15 and 20 kDa (L6) in the saliva of the UK group than in the TK group, and also showed stronger binding in the TK group than in the healthy group.

AAL showed stronger binding to one band between 15 and 20 kDa (L6) in the saliva of the UK group than to the TK and the healthy groups. On the contrary, Jacalin exhibited weaker binding to 2 bands between 100 and 250 kDa (L1, L2) and 1 band between 25 and 50 kDa (L6) in the saliva of the UK group than in the TK group, and also showed weaker binding in the TK group than in the healthy group (Figure 6).

HHL showed stronger binding to one band 70 kDa (L4) in the serum of the UK group than in the TK and healthy groups. PNA showed stronger binding to one band 70 kDa (L1) in the serum of the UK group than in the TK and healthy groups. On the contrary, PHA-E+L exhibited weaker binding to one band 50–70 kDa (L5) in the serum of the UK group than in the TK and healthy groups. AAL also exhibited weaker binding to one band 70–100 kDa (L2) and one band 50–70 kDa (L3) in the serum of the

Figure 3. a. Serous glycoprotein expression levels were determined with Cy3-labeled lectins using a lectin microarray. UK: untreated patients with KBD; TK: treated patients with KBD; Healthy: normal controls. The lectin microarrays revealed significant lectins marked with white rectangles. b. Significant differences in the lectin levels between the three groups. The bars show mean ± SD of three biological replicates from each group.
The results were coincident with the results from the lectin microarrays.

4. Discussion

Glycosylation is one of the most common posttranslational modifications of secreted proteins and plays a significant role in cell–cell interactions, cell adhesion, malignant transformation, and metastasis [10]. It also has an important role in the molecular recognition events of the body. The glycosylation patterns of glycoproteins provide clues about cell metabolism and the expression and function of oligosaccharides. Glycoproteins can exist in many glycosylated variants, and the distribution of different classes of oligosaccharide structures is most often specific for each glycosylation site [11].
Although serum is frequently used as a sample to analyze various biomarkers, saliva is also a good indicator of the plasma levels of various substances. Although both saliva and serum are samples from systemic sources, the components derived from tissues such as cartilage can accumulate in them. The extracellular matrices of tissues such as the cornea, hyaline cartilage, and nucleus pulposus of the intervertebral disks are rich sources of glycoproteins and proteoglycans (PGs) [12]. More importantly, shifts in the glycosylation patterns have been identified in diseases, such as in IgG of the serum of rheumatoid arthritis patients [13], which was later found to be responsible for the activation of the complement system [14]. Lectins can be valuable tools in the diagnosis of diseases, and even in discrimination of their stages [15], although the actual protein with altered glycosylation and/or its function would not be known.

In this study, the goal was to identify changes in glycosylation patterns in KBD by using a group of lectins. Hyaluronate treatment has been reported to alleviate the
symptoms of KBD patients [4]. Therefore, we also screened whether the treatment would reveal lectin levels, which are altered in KBD but normalized by hyaluronate therapy, since they could be useful in evaluating the efficacy of the treatment. As a result, the first screening experiments identified several lectins which had differential expression levels in the KBD saliva and serum in comparison to the normal samples. Three of those lectins (GSL-I, SNA, and Jacalin) were selected for the verification microarray of saliva samples, and three were selected for serum samples (HHL, PNA, and AAL). The carbohydrate chain Galα1-3-Gal is recognized by PNA, high mannose is recognized by HHL, and GlcNAc is recognized by AAL, Jacalin, and PHA-E+L.

The glycosylation pattern changes can have marked effects in the functions of proteins. Previously, the levels of the Galα1,3-Gal antigen reduced in HT-transgenic porcine cartilage conferred resistance to delayed rejection [16]. Expression levels of high mannose-type N-glycans were significantly increased at the later stages of mouse chondroprogenitor cell differentiation. On the other hand, the levels of some high mannose-type N-glycans were recently shown to be significantly decreased in both human OA cartilage and degraded mouse cartilage [17,18].

In developing rat embryos, the presence of numerous lectin binding affinities has been associated with a general reduction of oligosaccharide structures during development [19]. Primary OA chondrocytes are characterized by significantly higher levels of high mannose-type N-glycans and sialic acid-capped N-glycans compared to chondrocyte cell lines. In immortalized chondrocyte cell lines, the patterns of O- and N-linked oligosaccharides appear to be shifted toward reduced levels of high mannose-type and sialic acid-capped N-glycans, as well as increased levels of fucosylated O-glycosylation products [20]. An alteration in high mannose-type N-glycans has been attributed to the expression of the Mgat1 gene, which regulates the expression of the key proteases matrix metalloprotease-13 and aggreganase-2 during the cartilage degradation process [18]. Additionally, the levels of high mannose-type N-glycans in primary human chondrocytes decrease in response to inflammatory cytokines IL-1β and TNF-α [21]. The GlcNAc-accelerated production of hyaluronate is associated with the induction of hyaluronate synthase-2, a key enzyme involved in hyaluronate synthesis [22].

Intraarticular hyaluronate injection has been proposed to have many therapeutic mechanisms of action in the OA knee, including antiinflammatory effects, joint lubrication, shock absorption, chondroprotection, proteoglycan synthesis, and cartilage matrix alteration. At present, there are no good indicators for how to observe the biological effects of the treatment. Lectin analysis may be a potential assay for the follow-up of hyaluronate treatment, not only for KBD, but also for other forms of arthritis. In both the saliva and serum samples, HHL signal was stronger in the patients with KBD than in the normal controls and normalized after hyaluronate treatment. HHL binding was the best marker to differentiate the KBD patients from the controls. It also differentiated between the untreated and the hyaluronate-treated groups and, thus, might be a valid biomarker to evaluate the efficacy of the treatment. We plan to analyze the lectin levels in chondrocytes and to confirm diagnostic biomarkers of KBD in the next step. The method used to reveal the differences in the glycopatterns of human salivary and serous glycoproteins may provide pivotal information to help researchers understand other bone joint diseases. The selected lectins can only indicate changes in overall glycosylation patterns, but do not identify specific proteins involved. Therefore, the effects of these changes on protein functions cannot be defined by these analyses. However, it does not reduce the value which this type of assay can have in the diagnosis of KBD.

Acknowledgments
This study was supported by the National Natural Science Foundation of China (grant numbers: 81472924 and 81502766); National Natural Science Foundation of China key international cooperation projects (81620108026).

Contribution of authors
Sen WANG and Zongqiang GAO contributed equally to this work.
References

1. Wang S, Guo X, Wang W, Wang S. Genome-wide study identifies the regulatory gene networks and signaling pathways from chondrocyte and peripheral blood monocyte of Kashin–Beck disease. Genes to Cells 2012; 17(8): 619-632. doi: 10.1111/j.1365-2443.2012.01620.x

2. Gao Z, Guo X, Chen J, Duan C, Ma W et al. The effect of hyaluronic acid on the expression of IL-1β, TNF-α in chondrocytes of Kashin–Beck disease. Shaanxi Medical Journal 2015; 44(7): 774-778. doi: 10.3969/j.issn.1000-7377.2015.07.002

3. Gao Z, Guo X, Chen J, Duan C, Ma W et al. Effect of hyaluronic acid on collagen II and aggrecan mRNA expression in Kashin–Beck disease chondrocytes cultured in vitro. Journal of Clinical Rehabilitative Tissue Engineering Research 2009; 13(46): 9061-9065. doi: 10.3969/j.issn.1673-8225.2009.46.012

4. Xia CT, Yu FF, Ren FL, Fang H, Guo X. Hyaluronic acid and glucosamine sulfate for adult Kashin–Beck disease: a cluster-randomized, placebo-controlled study. Clinical Rheumatology 2016; 35(5): 1263-1270. doi: 10.1007/s10067-014-2809-6

5. Takeuchi H, Haltiwanger RS. Role of glycosylation of Notch in development. Seminars in Cell and Developmental Biology 2010; 21(6): 638-645. doi: 10.1016/j.semcdb.2010.03.003

6. Manning JC, Romero A, Habermann FA, Garcia Caballero G, Kaltner H et al. Lectins: a primer for histochemists and cell biologists. Histochemistry and Cell Biology 2017; 147(2): 199-222. doi: 10.1007/s00418-016-1524-6

7. Corfield AP, Berry M. Glycan variation and evolution in the eukaryotes. Trends in Biochemical Sciences 2015; 40(7): 351-359. doi: 10.1016/j.tibs.2015.04.004

8. Pilobello KT, Slaweck DE, Mahal LK. A ratiometric lectin microarray approach to analysis of the dynamic mammalian glycome. Proceedings of the National Academy of Sciences of the United States of America 2007; 104(28): 11534-11539. doi: 10.1073/pnas.0704954104

9. Qin X, Guo Y, Du H, Zhong Y, Zhang J et al. Comparative analysis for glycopatterns and complex-type N-glycans of glycoprotein in sera from chronic hepatitis B- and C-infected patients. Frontiers in Physiology 2017; 8: 596. doi: 10.3389/fphys.2017.00596

10. Liang Y, Ma T, Thakur A, Yu H, Gao L et al. Differentially expressed glycosylated patterns of alpha-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer. Glycobiology 2015; 25(3): 331-340. doi: 10.1093/glycob/cwu115

11. Dwek RA. Glycobiology: towards understanding the function of sugars. Biochemical Society Transactions 1995; 23(1): 1-25. doi: 10.1042/bst0230001

12. Plaa AH, West LA, Midura RJ. Keratan sulfate disaccharide composition determined by FACE analysis of keratanase II and endo-beta-galactosidase digestion products. Glycobiology 2001; 11(10): 779-790. doi: 10.1093/glycob/11.10.779

13. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985; 316(6027): 452-457. doi: 10.1038/316452a0

14. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nature Medicine 1995; 1(3): 237-243.

15. Coelho LC, Silva PM, Lima VL, Pontual EV, Paiva PM et al. Lectins, interconnecting proteins with biotechnological/pharmacological and therapeutic applications. Evidence-Based Complementary and Alternative Medicine 2017; 2017: 1594074. doi: 10.1155/2017/1594074

16. Costa C, Brokaw JL, Wang Y, Fodor WL. Delayed rejection of porcine cartilage is averted by transgenic expression of alpha1,2-fucosyltransferase. FASEB Journal 2003; 17(1): 109-111. doi: 10.1096/fj.02-0630fje

17. Urita A, Matsuhashi T, Onodera T, Nakagawa H, Hato M et al. Alterations of high-mannose type N-glycosylation in human and mouse osteoarthritis cartilage. Arthritis & Rheumatology 2011; 63(11): 3428-3438. doi: 10.1002/art.30584

18. Sethi MK, Thaysen-Andersen M, Smith JT, Baker MS, Packer NH et al. Comparative N-glycan profiling of colorectal cancer cell lines reveals unique bisecting GlcNAc and alpha-2,3-linked sialic acid determinants are associated with membrane proteins of the more metastatic/aggressive cell lines. Journal of Proteome Research 2014; 13(1): 277-288. doi: 10.1021/pr400861m

19. Zschaibitz A, Weiser H, Stooff E, Krahn V, Gabius HJ et al. Characterization of glycoconjugate expression during development of Meckel's cartilage in the rat. Anatomy and Embryology 1995; 191(1): 47-49.

20. Toegel S, Plattner VE, Wu SQ, Goldring MB, Chiari C et al. Lectin binding patterns reflect the phenotypic status of in vitro chondrocyte models. In Vitro Cellular & Developmental Biology – Animal 2009; 45(7): 351-360. doi: 10.1007/s11626-009-9186-5

21. Ishihara T, Kakiya K, Takahashi K, Miwa H, Rakushima M et al. Discovery of novel differentiation markers in the early stage of chondrogenesis by glycoform-focused reverse proteomics and genomics. Biochimica et Biophysica Acta 2014; 1840(1): 645-655. doi: 10.1016/j.bbadis.2013.10.027

22. Igarashi M, Sakamoto K, Nagaoka I. Effect of glucosamine, a therapeutic agent for osteoarthritis, on osteoblastic cell differentiation. International Journal of Molecular Medicine 2011; 28(3): 373-379. doi: 10.3892/ijmm.2011.686